Hepatocellular carcinoma - Insights
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer in the world. While HCC can be effectively treated in its early stages, most patients are not diagnosed until they are symptomatic and at higher grades and...
Bone and Soft Tissue Pathology Services at Mayo Cinic Laboratories
At Mayo Clinic, we excel in our approach to work collaboratively with radiology, surgery, and clinical practice to bring the highest quality.
Cytopathology Services at Mayo Clinic Laboratories
Pathologists from across the world send cases for the cytopathology section at Mayo Clinic to review. Learn more.
Test panel guides diagnosis of early onset IBD: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' test panel provides comprehensive evaluation of patients with suspected monogenic early onset inflammatory bowel disease, or IBD. Accurate diagnosis is key to guiding therapy...
In 2020, Mayo Clinic Laboratories launched more than 100 new tests. Driven by a patient-centered philosophy, our experts, laboratories, and facilities make it possible to develop new tests that transform medicine worldwide.
New tests launched in April - Insights
In April 2022, Mayo Clinic Laboratories announced fourteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Assay stratifies pregnant women's preeclampsia risk: Joshua Bornhorst, Ph.D. - Insights
Joshua Bornhorst, Ph.D., explains how Mayo Clinic Laboratories' unique assay identifies pregnant women at risk of developing preeclampsia with severe features. Test results can guide clinical management, to safeguard maternal and neonatal...
Communiqué Archives - Page 4 of 4 - Insights
Skip to Content MayoACCESS MayoLINK...
Autoimmune Gastrointestinal Dysmotility Evaluation [Test in Focus] - Insights
Divyanshu (Div), Dubey, M.B.B.S, gives an overview of the new Autoimmune Gastrointestinal Dysmotility Evaluation available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to...
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D. - Insights
Maryam Shahi, M.D., explains how Mayo Clinic Laboratories' unique biomarker test (TEST ID: AFOLR) determines which patients would likely benefit from a new treatment for recurrent epithelial ovarian cancer. Disease recurrence is common, and...